Available on-demand | 30 min
Breakthroughs in gene therapy depend on the ability to build and deliver large, complex DNA constructs quickly, reliably, and at scale. Yet constructs over 5 kb, or those containing LTRs and intricate genomic elements, continue to strain traditional synthesis methods. Even once you have the DNA, today’s go-to delivery vehicles (AAVs, LNPs) often can’t handle those oversized cargoes efficiently.
In this joint webinar, EndoFold, Inc. and Ansa Biotechnologies share results from a proof-of-concept collaboration demonstrating a new path forward: ultra-rapid synthesis of full-length therapeutic constructs paired with next-generation, designable delivery vehicles.